{"entity":{"id":"paper-fader-trastuzumab-uterine-serous-jco-2018","kind":"paper","name":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","aka":[],"tldr":"Adding trastuzumab to chemotherapy for HER2-positive uterine serous carcinoma, an aggressive endometrial cancer, lengthened progression-free survival by about four months and later showed a survival benefit, making HER2 testing routine in this subtype.","summary":"Randomised phase 2 trial of 61 women with HER2-positive (immunohistochemistry 3+ or amplified) advanced or recurrent uterine serous carcinoma treated with carboplatin-paclitaxel with or without trastuzumab continued as maintenance.\n\nMedian progression-free survival was 12.6 versus 8.0 months (hazard ratio 0.44), with the largest gain in newly diagnosed stage III to IV disease (17.9 versus 9.3 months); an update showed improved overall survival in that group.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2018","url":"https://doi.org/10.1200/JCO.2017.76.5966"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29584549/"}],"tags":[],"related":[],"cancers":["endometrial-p53-abnormal"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/JCO.2017.76.5966","pmid":"29584549","authors":"Fader AN, Roque DM, Siegel E, et al.","paperType":"rct","findings":["Median progression-free survival 12.6 vs 8.0 months; hazard ratio 0.44.","Stage III to IV newly diagnosed: 17.9 vs 9.3 months, with an overall survival benefit on update."],"whatItMeans":"HER2 testing of every serous endometrial cancer and trastuzumab with first-line chemotherapy for HER2-positive advanced disease are now guideline recommendations; trastuzumab deruxtecan extends the option.","caveats":["Small phase 2 trial.","About 30 percent of uterine serous carcinomas are HER2-positive; benefit in lower expression is unknown."],"changedPractice":true,"participants":61},"route":"/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/","neighbours":{"cancer":[{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}